Federated Hermes Inc. Has $4.23 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Federated Hermes Inc. lifted its holdings in shares of Glaukos Co. (NYSE:GKOS) by 1.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,224 shares of the medical instruments supplier’s stock after purchasing an additional 501 shares during the quarter. Federated Hermes Inc.’s holdings in Glaukos were worth $4,232,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of GKOS. Harbor Capital Advisors Inc. bought a new stake in Glaukos during the 4th quarter worth about $3,679,000. Sanctuary Advisors LLC bought a new stake in Glaukos in the 3rd quarter valued at $258,000. Rhumbline Advisers boosted its position in shares of Glaukos by 0.3% in the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier’s stock valued at $21,260,000 after acquiring an additional 403 shares during the period. IFP Advisors Inc acquired a new position in shares of Glaukos during the 4th quarter worth approximately $43,000. Finally, US Bancorp DE grew its position in Glaukos by 8.3% during the fourth quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier’s stock worth $914,000 after buying an additional 470 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

GKOS stock opened at $90.05 on Friday. The company has a market capitalization of $5.09 billion, a P/E ratio of -31.38 and a beta of 0.88. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52-week low of $77.91 and a 52-week high of $163.71. The business has a 50-day simple moving average of $114.19 and a two-hundred day simple moving average of $132.66.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Research analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Activity

In related news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

GKOS has been the topic of several recent analyst reports. Stifel Nicolaus raised their target price on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Truist Financial decreased their price target on shares of Glaukos from $185.00 to $140.00 and set a “buy” rating for the company in a research report on Friday. Wells Fargo & Company raised their price objective on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Finally, Needham & Company LLC lifted their target price on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.50.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.